國立高雄大學圖資館 |

Language: English

Back

Alzheimer's disease and the eye

Record Type:	Electronic resources : Monograph/item
Title/Author:	Alzheimer's disease and the eyeby Jeffrey N. Weiss.
Author:	Weiss, Jeffrey N.
Published:	Cham :Springer Nature Switzerland :2024.
Description:	x, 139 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	Alzheimer's diseaseTreatment
Online resource:	https://doi.org/10.1007/978-3-031-58811-2
ISBN:	9783031588112$q(electronic bk.)

Alzheimer's disease and the eye
Weiss, Jeffrey N.

Alzheimer's disease and the eye[electronic resource] /by Jeffrey N. Weiss. - Cham :Springer Nature Switzerland :2024. - x, 139 p. :ill., digital ;24 cm.

Part 1: Introduction -- Chapter 1. Alzheimer's Disease -- Chapter 2. Rates of Dementia -- Chapter 3. Biomarkers and Clinical Endpoints -- Chapter 4. Ocular Biomarkers -- Part 2: Diagnosis -- Chapter 5. Biochemical and Neuroimaging -- Chapter 6. Cognitive Decline -- Chapter 7. EEG/ERP -- Chapter 8. Eye Tracking -- Chapter 9. Light Intervention -- Chapter 10. Retina -- Chapter 11. Tears -- Chapter 12. Telemedicine -- Chapter 13. Virtual Reality -- Part 3: Treatment -- Chapter 14. Recruiting Trials in the US -- Chapter 15. Not Yet Recruiting Trials in the US.

This book is a compendium of the worldwide studies of Alzheimer's disease utilizing the eye as a biomarker, or as a treatment method, that are registered with the United States National Institutes of Health website, clinicaltrials.gov. Clinicaltrials.gov is the largest listing of research studies in the world. The study titles are provided, as is the country of origin and the Clinical Trial Number in order to make it easier for the reader to locate the study and obtain further information. New drug development is costly and time consuming. If through the use of biomarkers, study durations and research costs decrease, there is a greater possibility of a new and effective drug to treat this devastating disease. The eye offers the possibility of early diagnosis and of treatment. Alzheimer's Disease and the Eye is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.

ISBN: 9783031588112$q(electronic bk.)

Standard No.: 10.1007/978-3-031-58811-2doiSubjects--Topical Terms:

969761
Alzheimer's disease
--Treatment

LC Class. No.: RC523

Dewey Class. No.: 616.831106

Alzheimer's disease and the eye
LDR:02405nmm a2200325 a 4500 001 658556
003 DE-He213
005 20240702131421.0
006 m d
007 cr nn 008maaau
008 240923s2024 sz s 0 eng d
020 $a 9783031588112$q(electronic bk.)
020 $a 9783031588105$q(paper)
024 7 $a 10.1007/978-3-031-58811-2 $2 doi
035 $a 978-3-031-58811-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RC523
072 7 $a MJQ $2 bicssc
072 7 $a MED063000 $2 bisacsh
072 7 $a MJQ $2 thema
082 0 4 $a 616.831106 $2 23
090 $a RC523 $b .W431 2024
100 1 $a Weiss, Jeffrey N. $3 888686
245 1 0 $a Alzheimer's disease and the eye $h [electronic resource] / $c by Jeffrey N. Weiss.
260 $a Cham : $b Springer Nature Switzerland : $b Imprint: Springer, $c 2024.
300 $a x, 139 p. : $b ill., digital ; $c 24 cm.
505 0 $a Part 1: Introduction -- Chapter 1. Alzheimer's Disease -- Chapter 2. Rates of Dementia -- Chapter 3. Biomarkers and Clinical Endpoints -- Chapter 4. Ocular Biomarkers -- Part 2: Diagnosis -- Chapter 5. Biochemical and Neuroimaging -- Chapter 6. Cognitive Decline -- Chapter 7. EEG/ERP -- Chapter 8. Eye Tracking -- Chapter 9. Light Intervention -- Chapter 10. Retina -- Chapter 11. Tears -- Chapter 12. Telemedicine -- Chapter 13. Virtual Reality -- Part 3: Treatment -- Chapter 14. Recruiting Trials in the US -- Chapter 15. Not Yet Recruiting Trials in the US.
520 $a This book is a compendium of the worldwide studies of Alzheimer's disease utilizing the eye as a biomarker, or as a treatment method, that are registered with the United States National Institutes of Health website, clinicaltrials.gov. Clinicaltrials.gov is the largest listing of research studies in the world. The study titles are provided, as is the country of origin and the Clinical Trial Number in order to make it easier for the reader to locate the study and obtain further information. New drug development is costly and time consuming. If through the use of biomarkers, study durations and research costs decrease, there is a greater possibility of a new and effective drug to treat this devastating disease. The eye offers the possibility of early diagnosis and of treatment. Alzheimer's Disease and the Eye is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.
650 0 $a Alzheimer's disease $x Treatment $x Research. $3 969761
650 0 $a Ocular manifestations of general diseases. $3 280447
650 1 4 $a Ophthalmology. $3 274149
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-58811-2
950 $a Medicine (SpringerNature-11650)